Biotechnology

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

Boutique investment bank Brookline snags four senior pros, signaling a strategic deepening of its expertise in the competitive healthcare and SPAC sectors.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

The deal merges BlueRidge's broad life sciences support with Design Science's niche expertise in usability, a critical and mandatory field for FDA approval.

With two major trial results looming, Zura Bio appoints Sandeep Kulkarni, who led Tourmaline to a Novartis sale, to navigate its high-stakes future.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.

The Drug Information Association's new platform aims to help startups overcome funding and regulatory hurdles, connecting them to investors and experts.

A new partnership aims to accelerate mental health innovation by combining a national research network with deep community-based expertise in CNS trials.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

After a $16.5M funding round, the smart-shipping innovator hires a top finance exec to scale its attack on the $35B problem of spoiled medicine.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

With $35.1M in new funding, Infinitopes is launching a human trial for its AI-designed vaccine aimed at preventing oesophageal cancer recurrence.